60 likes | 176 Views
2011-04-11 Live Demonstration at the EGI User Forum – Vilnius, Lithuania David Manset, maatG France Isabella Castiglioni, CNR/IBFM Andrea Schenone, University of Genoa And On Behalf of DECIDE Project Consortium.
E N D
2011-04-11 Live Demonstration at the EGI User Forum – Vilnius, Lithuania David Manset, maatG France Isabella Castiglioni, CNR/IBFM Andrea Schenone, University of Genoa And On Behalf of DECIDE Project Consortium DECIDE(Diagnostic Enhancement of Confidence by an International Distributed Environment) Presenters David Manset – maatG France DECIDE SA Coordinator Valeria Ardizzone - COMETA DECIDE Technical Coordinator
Consortium • To provide the Neuroscientific and Medical community with a dedicatedGrid-based e-Infrastructure • To deploy a secure and user-friendly servicefor the earlydiagnosis and researchon dementia and other brain diseases • To validatethe e-Infrastructure and the services • To propose a long-termvision for the sustainabilityof the e-Infrastructure • To disseminate the results and providetraining programmes Objectives David Manset - maatG 2011-04-11 EGI User Forum Demonstration
GRID INFRASTRUCTURE e-Infrastructure Production quality e-Infrastructure to service translational research • Grid-based Infrastructure • EGI gLite middleware, • Builds on neuGRID/outGRID, • ROC certifiedresources, • QoSdefined by SLA, • 10 Grid Sites, • 6 Production, • 4 Pre-Production, • More than 600 dedicated CPU cores, • Can expand to LSGC resources DECIDE PLATFORM • GEANT & NRENs Internet Network • High-capacitybandwidths, • Production sites, • From 100 Mbps to 1Gbps CONNECTIVITY . INFRASTRUCTURE David Manset - maatG 2011-04-11 EGI User Forum Demonstration
Early Diagnostic of AD • Alzheimer’s Disease (AD) marker • SPM shows AD progression, • From Mild Cognitive Impairment (MCI) to AD, • Marker highlights typical spatial patterns, • Allows measuring disease evolution, • Used to diagnose disease stage, • Interesting for early diagnostic of AD, • Adapted treatment and care Patient with Mild Cognitive Impairment (MCI) and progressed in AD after 1 year • Marker specificities • Requires lots of norma-controls (i.e. healthy patients) data, • The more data, the more accurate, • Norma-control is rare data, • As itrequiresexposing patients to radioactive material, • Strongethicalregulationsat national/regionallevels, • e.g. no children data etc Hypocaptation of radioactivetracer (FDG) asmeasured from PET imaging Yellow regionsidentified by SPM in the MCI phase (retrosplenialcortex and bilateraltemporal-parietal) are typical AD pattern David Manset - maatG 2011-04-11 EGI User Forum Demonstration
Early Diagnostic of AD • Why the Grid? • Grid as a federateddatabase of norma-controlsacrossparticipatingcenters • Gridallowssharing withoutmoving/copyingdata, • Single virtualrepositoryof such rare data • Gridprovidescomputational power to access, process and store diagnostic results, • Norma-controls are re-processedeach time a diagnostic isrequested, • SPM expectedto berun 5-10x/year/patient (1) Spatial Normalization allows comparing images (2) Checks patient against normal parameters distribution (3) Statistically infers data to highlight regions of hypo-captations SPM processing steps. David Manset - maatG 2011-04-11 EGI User Forum Demonstration
e-Infrastructure • LifeRay-based Web portal • Diagnostic services as Portlets • User-friendly access • Simple login + password • Single Sign On + Shibboleth • Multiple IdP security architecture • Robot-certificate mapping David Manset - maatG 2011-04-11 EGI User Forum Demonstration Demonstration: www.eu-decide.eu